Laboratory attitudes and practices in the conservation of biological tissues for research purposes in Cote d'Ivoire

Background : Since 2009, Côte d'Ivoire has had a biobank, which now houses the ECOWAS regional biobank. This biobank intends to set up a biological tissue bank for research. In Côte d'Ivoire, several public and private structures handle biological tissues. However, we do not know which ones are involved in the conservation of biological tissues and their related procedures. To ensure optimal conservation of biological tissues at the biobank of Côte d'Ivoire, it is necessary to conduct a study on the state of the art of tissue preservation in Côte d'Ivoire. The objective of our work is to know the attitudes and practices of biological tissue preservation in Côte d'Ivoire.Methods : This is a descriptive study carried out in biological analysis laboratories in the south of the Ivory Coast.Results : A total of 66 laboratories agreed to answer the questionnaire that was proposed to them. Among them, only 21.21% kept biological tissues, of which 42.86% were human tissues, 35.71% animal tissues and 21.43% plant tissues. Human tissuesz were stored in formalin at room temperature for a period ranging from 2 weeks to 6 months. Animal biopsies and surgical specimens were stored in formalin and at -80°C for an indefinite period of time. Plant tissues were stored at room temperature and +4°C for an indefinite period of time.Conclusion : The conservation quality of biological tissues still needs to be improved

Early Life Nutrition Factors and Risk of Acute Leukemia in Children: Systematic Review and Meta-Analysis

Acute leukemia commonly occurs in young children with peak incidence at the age of 2–5 years. However, the etiology is still unclear and many preventable risk factors still deserve to be reviewed. The focus of this systematic review and meta-analysis is to summarize the evidence concerning early life nourishment (breastfeeding, early life diet), neonatal vitamin K administration and the risk of acute leukemia. All epidemiological studies published up to June 2023 and assessing diet-related risk factors for childhood acute leukemia were identified in two electronic databases (PubMed and Web of Science), with no limits on publication year or language. A total of 38 studies (37 case–control studies and 1 study with pooled analysis) were included. The published risk estimates were combined into a meta-analysis using the Generic Inverse Variance method. The current evidence shows that breastfeeding (yes vs. no) has a protective effect against acute lymphoblastic leukemia (odds ratio = 0.85; 95% CI, 0.76–0.94). Evidence related to the role of other studied factors (foods and supplements) is inconclusive. Further research into the potential role of diet in early life and the risk of acute leukemia is needed to develop prevention strategies at population level. Review Registration: PROSPERO registration no. CRD42019128937

Valeur pronostique de l'expression de l'annexine A1 et des formylpeptid receptors (FPR) par les melanomes primitifs (une étude pilote)

Notre équipe a montré que l'expression de l'annexine A1 (ANXA1) (ligand des FPR) est augmentée d'un facteur 2 dans la lignée murine B16/BL6, métastatique par rapport à la lignée B16F10 dont elle dérive. La diminution du taux d'ANXA1 par ARN interférence diminue in vitro les propriétés d'invasion de cette lignée B16/BL6. L'ANXA1 pourrait donc être impliquée dans le processus d'invasion du mélanome. L'objectif est d'estimer chez l'humain la valeur pronostique de l'expression de l'ANXA1 et des FPR dans les mélanomes primitifs. Les expressions de l'ANXA1 et des FPR ont été recherchées en immuno-histochimie sur 36 mélanomes primitifs et leurs métastases lorsqu'elles étaient disponibles. Une expression positive de l'ANXA1 était associée à un excès de risque de métastase à 6,0. L'expression de l'ANXA1 n'augmentait pas avec l'indice de Breslow. Les 2 mélanomes d'indice de Breslow inférieur à 1 mm qui ont été métastasé exprimaient l'ANXA1. En conclusion, l'ANXA1 semble particulièrement intéressante pour détecter les mélanomes à potentiel métastatique en particulier ceux de faible indice de Breslow.CLERMONT FD-BCIU-Santé (631132104) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF

Immunological considerations for laboratory staff and COVID-19 biosafety

The vulnerability of healthcare and laboratory to potential infection by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus has thus far been analyzed through the lens of the acute phase of the pandemic, including remote-based work, as well as emergency settings that are different from routine healthcare operations. However, as lockdowns ease and activities return to an identifiable pre-pandemic routine, the safety considerations also require to shift accordingly. As laboratory workers are likely to continue being exposed to unidentified SARS-CoV-2 positive samples through routine blood collection and processing operations, coronavirus disease 2019 (COVID-19) might have to be re-considered as an occupational disease within this context. Additionally, as per many such occupational diseases, a surveillance system is implemented for the medium- and long-term. This manuscript presents the views on the possible surveillance scenarios for laboratory staff, viewed from an immunological and biosafety perspective

Biological quality evaluation of samples stored in biobank of Pasteur Institute of Côte d'Ivoire : case of influenza in nasopharyngeal and meningococcal in cerebrospinal fluid (CSF) samples

The preservation and use of biological samples for therapy, diagnosis and research have been common practice for a long time. To maintain the stability of biomolecules (DNA, RNA, proteins) contained in the samples stored at the biobank of Pasteur Institute of Côte d'Ivoire, we evaluated the quality of the conservation of influenza nasopharyngeal and meningococcal CSF samples. Two (2) samples were chosen for this evaluation, namely Influenza A nasopharyngeal samples and Streptococcus pneumoniae CSF samples. After a few years of storage, these same samples were used to perform a PCR test. The results of the PCR tests showed a discordance of 36.4% for the Streptococcus pneumoniae CSF samples compared to 15.4% for the nasophryngeal samples. This study validates the need to write procedures for sample conservation at the level of the analysis laboratories and the Biobank. Therefore, a reflection must be carried out to standardise conservation techniques and a sample conservation evaluation programme

Annexin A1 in primary tumors promotes melanoma dissemination

International audienc

Risk factors for NSF: A literature review

Emerging evidence linking gadolinium-based contrast agents (GBCAs) to nephrogenic systemic fibrosis (NSF) has changed medical practice patterns toward forgoing GBCA-enhanced magnetic resonance imaging (MRI) or substituting other imaging methods, which are potentially less accurate and often radiation-based. This shift has been based on reports of high NSF incidence at sites where a confluence of risk factors occurred in patients with severe renal dysfunction. This review article explores the factors that affect NSF risk, compares risks of alternative imaging procedures, and demonstrates how risk can be managed by careful selection of GBCA dose, timing of injection with respect to dialysis, and other factors. Nearly half of NSF cases are a milder form that does not cause contractures or reduce mobility. It appears that eliminating even a single risk factor can reduce NSF incidence/risk at least 10-fold. Elimination of multiple risk factors by using single-dose GBCA, dialyzing dialysis patients quickly following GBCA administration, avoiding GBCA in acute renal failure while serum creatinine is rising, and avoiding nonionic linear GBCA in renal failure patients may reduce NSF risk more than a thousand-fold, thereby allowing safe GBCA-enhanced MRI in virtually all patients

NEPHROGENIC SYSTEMIC FIBROSIS: REVIEW OF 408 BIOPSY-CONFIRMED CASES

Nephrogenic systemic fibrosis (NSF) has now been virtually eliminated by the discovery of its association with gadolinium-based contrast agents (GBCAs) and the consequent reduced use of GBCA-enhanced magnetic resonance imaging (MRI) in severe renal failure patients. This review of 408 biopsy-confirmed cases shows how to minimize NSF risk when performing GBCA-enhanced MRI or magnetic resonance angiography. The absence of any NSF cases in patients less than 8 years old or greater than 87 years old suggests that infants and elderly patients are already protected. Limiting GBCA dose to a maximum of 0.1 mMol/kg, dialyzing dialysis patients quickly following GBCA administration, delaying administration of GBCA in acute renal failure until after renal function returns or dialysis is initiated, and avoiding nonionic linear GBCA in renal failure patients, especially when there are pro-inflammatory conditions, appear to have reduced NSF risk to the point where safe GBCA-enhanced MRI is possible in most patients

Nephrogenic systemic fibrosis: review of 370 biopsy-confirmed cases

Discovery of an association between gadolinium-based contrast agents (GBCAs) and nephrogenic systemic fibrosis (NSF) has led to less use of GBCA-enhanced magnetic resonance imaging in dialysis patients and patients with severe renal failure at risk of NSF, and the virtual elimination of new cases of NSF. But shifting patients with renal failure to alternative imaging methods may subject patients to other risks (e.g., ionizing radiation or iodinated contrast). This review paper examines 370 NSF cases reported in 98 articles to analyze NSF risk factors. Eliminating multiple risk factors by limiting GBCA dose to a maximum of 0.1 mmol/kg, dialyzing patients undergoing dialysis quickly following GBCA administration, delaying GBCA in acute renal failure until after renal function returns or dialysis is initiated, and avoiding nonionic linear GBCA in patients with renal failure especially when there are proinflammatory conditions may substantially reduce the risk of NSF

European dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis

none44noneKnobler, R.*; Moinzadeh, P.; Hunzelmann, N.; Kreuter, A.; Cozzio, A.; Mouthon, L.; Cutolo, M.; Rongioletti, F.; Denton, C.P.; Rudnicka, L.; Frasin, L.A.; Smith, V.; Gabrielli, A.; Aberer, E.; Bagot, M.; Bali, G.; Bouaziz, J.; Braae Olesen, A.; Foeldvari, I.; Frances, C.; Jalili, A.; Just, U.; Kähäri, V.; Kárpáti, S.; Kofoed, K.; Krasowska, D.; Olszewska, M.; Orteu, C.; Panelius, J.; Parodi, A.; Petit, A.; Quaglino, P.; Ranki, A.; Sanchez Schmidt, J.M.; Seneschal, J.; Skrok, A.; Sticherling, M.; Sunderkötter, C.; Taieb, A.; Tanew, A.; Wolf, P.; Worm, M.; Wutte, N.J.; Krieg, T.Knobler, R.; Moinzadeh, P.; Hunzelmann, N.; Kreuter, A.; Cozzio, A.; Mouthon, L.; Cutolo, M.; Rongioletti, F.; Denton, C. P.; Rudnicka, L.; Frasin, L. A.; Smith, V.; Gabrielli, A.; Aberer, E.; Bagot, M.; Bali, G.; Bouaziz, J.; Braae Olesen, A.; Foeldvari, I.; Frances, C.; Jalili, A.; Just, U.; Kähäri, V.; Kárpáti, S.; Kofoed, K.; Krasowska, D.; Olszewska, M.; Orteu, C.; Panelius, J.; Parodi, A.; Petit, A.; Quaglino, P.; Ranki, A.; Sanchez Schmidt, J. M.; Seneschal, J.; Skrok, A.; Sticherling, M.; Sunderkötter, C.; Taieb, A.; Tanew, A.; Wolf, P.; Worm, M.; Wutte, N. J.; Krieg, T